Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6012888 | 1.00 | CCR5 (0.98) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL6012730 | 1.00 | CCR5 (0.98) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL30241423 | 1.00 | CCR5 (0.98) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL6012483 | 1.00 | CCR5 (0.98) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5612305 | 0.99 | CCR5 (1.00) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5611955 | 0.99 | CCR5 (1.00) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5612796 | 0.99 | CCR5 (1.00) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5612463 | 0.99 | CCR5 (1.00) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL6012759 | 0.99 | CCR5 (0.97) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5612396 | 0.98 | CCR5 (0.98) | CCR5CHRM3SIGMAR1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844353-B2 | Microorganisms for the production of insect pheromones and related compounds | PROVIVI, INC. (US) | 2023-12-19 | — | — | US | claimed |
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | claimed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | claimed |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | PANASONIC CORPORATION (JP) | 2004-05-20 | — | — | US | claimed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | claimed |
| CN-223009445-U | Heated massage wheel | 浙江热丽科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250128208-A1 | ALKALINE CATION ENRICHMENT AND WATER ELECTROLYSIS TO PROVIDE CO2 MINERALIZATION AND GLOBAL-SCALE CARBON MANAGEMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-24 | — | — | US | disclosed |
| US-12161972-B2 | Alkaline cation enrichment and water electrolysis to provide CO2 mineralization and global-scale carbon management | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4397394-A1 | ALKALINE CATION ENRICHMENT AND WATER ELECTROLYSIS TO PROVIDE COMINERALIZATION AND GLOBAL-SCALE CARBON MANAGEMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20060282123-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2006-12-14 | — | — | US | disclosed |
| US-20060160859-A1 | Method for treating HIV infection through co-administration of tipranavir and GW873140 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006060177-A1 | METHOD FOR TREATING HIV INFECTION THROUGH CO-ADMINISTRATION OF TIPRANAVIR AND GW873140 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20050196421-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-08 | — | — | US | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1438962-A1 | DRUGS COMPRISING COMBINATION OF TRIAZASPIRO 5,5 U NDECANE DERIVATIVE WITH CYTOCHROME P450 ISOZYME 3A4 INHIBITOR AND/OR P−GLYCOPROTEIN INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844353-B2 | Microorganisms for the production of insect pheromones and related compounds | FASN, ACSL4, FADS1 | CCR5 258/4885CHRM3 726/4885SIGMAR1 3079/4885 |
| US-20060160859-A1 | Method for treating HIV infection through co-administration of tipranavir and GW873140 | NAA40, TRIM25, CD4 | CCR5 14/4885CHRM3 3462/4885SIGMAR1 2274/4885 |
| US-12016935-B2 | Methods for detecting CCR2 receptors | CCR2, CCR1, CCR5 | CCR5 3/4885CHRM3 466/4885SIGMAR1 345/4885 |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | CXCR5, CCL11, ACKR3 | CCR5 5/4885CHRM3 2484/4885SIGMAR1 97/4885 |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | CCR5 3909/4885CHRM3 3011/4885SIGMAR1 3840/4885 |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | CCR5 3909/4885CHRM3 3011/4885SIGMAR1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.